

May 15, 2025

To all stakeholders,

Perseus Proteomics Inc.
Securities Code: 4882 Growth TSE
ir@ppmx.com

Notice on Recording of Non-operating Income, Non-operating Expenses, and Extraordinary Losses

Perseus Proteomics Inc. (The Company) announces that the non-operating income, non-operating expenses, and extraordinary losses were recorded in the fiscal year ended March 31, 2025. The details are as follows:

1. Non-operating income

The Company has recorded interest income of 1,951 thousand yen and outsourcing service income of 1,772 thousand yen as non-operating income respectively.

2. Non-operating expenses

The Company has recorded taxes and dues associated with capital increase through exercise of share acquisition rights of 3,271 thousand yen, foreign exchange losses of 2,887 thousand yen, and share issuance costs of 961 thousand yen as non-operating expenses respectively.

3. Extraordinary losses

The Company has recorded impairment losses of 72,510 thousand yen for its non-current assets in accordance with the Accounting Standard for Impairment of Fixed Assets as extraordinary losses.

4. Impact on financial results

The above items have been fully reflected in the “Financial Results for the Fiscal Year Ended March 31, 2025” announced today.

END